A Double-blind, Placebo-controlled Study to Evaluate the Effect of GS-6615 on QT, Safety and Tolerability in Subjects With Long QT2 Syndrome

Trial Profile

A Double-blind, Placebo-controlled Study to Evaluate the Effect of GS-6615 on QT, Safety and Tolerability in Subjects With Long QT2 Syndrome

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jul 2016

At a glance

  • Drugs Eleclazine (Primary)
  • Indications Long QT syndrome
  • Focus Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 11 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 23 May 2016 Status changed from recruiting to active, no longer recruiting.
    • 15 Apr 2016 Planned End Date changed from 1 Apr 2016 to 1 Jun 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top